Mortality for Critical Congenital Heart Diseases and Associated Risk Factors in
            Newborns. A Cohort Study

Soares, Andressa Mussi

doi:10.5935/abc.20180203

Cited by 8 publications

(8 citation statements)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should be highlighted that the number of deaths related to CHD is officially lower than in fact it should be. Underreporting in Brasil remains a constant reality since newborns often leave hospital clinically well, and on arrival at home begin to degenerate, thereby dying without hospital records registering the true cause of death 10,12 .…”

Section: Discussionmentioning

confidence: 99%

Mortality due to congenital heart disease in Pernambuco from 1996 to 2016

Cabral

Guimarães

Filho

et al. 2020

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SUMMARY BACKGROUND To determine the magnitude and temporal trends of deaths due to congenital heart disease (CHD) in Pernambuco between 1996 and 2016. METHODS This was an ecological, time-series study, involving all cases of deaths from congenital cardiovascular malformations in the state of Pernambuco, from 1996 to 2016, using data from DATASUS, SINASC and SIM. RESULTS There were 3,584 deaths from congenital cardiovascular malformations amongst individuals aged 0 to 14 years, of which 81.94% were concentrated in children aged under one year. The infant mortality rate (IMR) presented a linear growth trend of 0.4645 per year (p <0.01). The cause-of-death code Q24 (other congenital malformations of the heart) was present in 72.54% of the death records and 48.17% of the deaths occurred in infants aged between 28 and 364 days of life. The highest occurrence of deaths was identified in children with low birth weight (500 and 1,499g), male, premature, children of mothers without schooling, in deliveries at home (p <0.05). CONCLUSIONS Congenital heart disease still represents a public health problem as a cause of death, particularly in the first year of life, with IMR in a linear growth trend. Deaths from CHD were more prevalent in male children, born prematurely, with low birth weight, born to mothers with low schooling and deliveries without medical care.

show abstract

Section: Discussionmentioning

confidence: 99%

Mortality due to congenital heart disease in Pernambuco from 1996 to 2016

Cabral

Guimarães

Filho

et al. 2020

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…Congenital heart disease is the leading cause of early postnatal mortality ( Soares, 2018 ). Therefore, in fetuses with increased NT due to cardiac anomalies, it may have a significant impact on prenatal as well as postnatal pathophysiology.…”

Section: Cardiac Anomalymentioning

confidence: 99%

Fetal nuchal edema and developmental anomalies caused by gene mutations in mice

Sugiyama

Hirashima²

2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Fetal nuchal edema, a subcutaneous accumulation of extracellular fluid in the fetal neck, is detected as increased nuchal translucency (NT) by ultrasonography in the first trimester of pregnancy. It has been demonstrated that increased NT is associated with chromosomal anomalies and genetic syndromes accompanied with fetal malformations such as defective lymphatic vascular development, cardiac anomalies, anemia, and a wide range of other fetal anomalies. However, in many clinical cases of increased NT, causative genes, pathogenesis and prognosis have not been elucidated in humans. On the other hand, a large number of gene mutations have been reported to induce fetal nuchal edema in mouse models. Here, we review the relationship between the gene mutants causing fetal nuchal edema with defective lymphatic vascular development, cardiac anomalies, anemia and blood vascular endothelial barrier anomalies in mice. Moreover, we discuss how studies using gene mutant mouse models will be useful in developing diagnostic method and predicting prognosis.

show abstract

“…Congenital heart disease (CHD) describes a set of cardiac structural malformations resulting from alterations during embryonic organogenesis [ 1 ]. Currently, CHD is recognized as the leading cause of mortality from birth defects [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Congenital Heart Disease: The State-of-the-Art on Its Pharmacological Therapeutics

Varela-Chinchilla

Sánchez-Mejía

Trinidad-Calderón

2022

JCDD

View full text Add to dashboard Cite

Congenital heart disease is one of the most common causes of death derived from malformations. Historically, its treatment has depended on timely diagnosis and early pharmacological and surgical interventions. Survival rates for patients with this disease have increased, primarily due to advancements in therapeutic choices, but mortality remains high. Since this disease is a time-sensitive pathology, pharmacological interventions are needed to improve clinical outcomes. Therefore, we analyzed the applications, dosage, and side effects of drugs currently used for treating congenital heart disease. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and potassium-sparing diuretics have shown a mortality benefit in most patients. Other therapies, such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostaglandins, and soluble guanylyl cyclase stimulators, have benefited patients with pulmonary artery hypertension. Likewise, the adjunctive symptomatic treatment of these patients has further improved the outcomes, since antiarrhythmics, digoxin, and non-steroidal anti-inflammatory drugs have shown their benefits in these cases. Conclusively, these drugs also carry the risk of troublesome adverse effects, such as electrolyte imbalances and hemodynamic compromise. However, their benefits for survival, symptom improvement, and stabilization outweigh the possible complications from their use. Thus, cases must be assessed individually to accurately identify interventions that would be most beneficial for patients.

show abstract

Mortality for Critical Congenital Heart Diseases and Associated Risk Factors in Newborns. A Cohort Study

Cited by 8 publications

References 6 publications

Mortality due to congenital heart disease in Pernambuco from 1996 to 2016

Mortality due to congenital heart disease in Pernambuco from 1996 to 2016

Fetal nuchal edema and developmental anomalies caused by gene mutations in mice

Congenital Heart Disease: The State-of-the-Art on Its Pharmacological Therapeutics

Contact Info

Product

Resources

About